|
Program : GBR 600 – Monoclonal Antibody (mAB) |
Phase I |
|
|
| Target /Indication |
GBR 600 is a monoclonal antibody against the human von Willebrand Factor. This product is being developed as an injectible anti-platelet agent for the treatment of acute coronary syndrome. |
| Highlights |
| |
|
GBR 600 presents a novel mechanism of action. |
| |
|
GBR 600 has the potential to offer strong efficacy based on outstanding potency demonstrated in-vivo models. |
| |
|
Despite its excellent efficacy, GBR 600 has a favourable safety profile compared to products in this class, especially relating to risk of bleeding. GBR 600 also has a large therapeutic window. |
| |
|
GBR 600 is being developed for the prevention of thrombosis in patients at risk such as cerebral and cardiac ischemia and acute coronary syndrome. |
| |
|
GBR 600 has received approval for undertaking Phase I trials in Europe. |
|
| Market Opportunity |
| |
|
Current Market : USD 2 bn |
| |
|
GBR-600 has the potential to significantly expand the
current market by offering improved efficacy with
favorable adverse event profile |
|
| Potential Peak Sales
|
USD 1 bn |
|
